"Papillomavirus Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
| Descriptor ID |
D053918
|
| MeSH Number(s) |
D20.215.894.899.498
|
| Concept/Terms |
Human Papillomavirus Vaccines- Human Papillomavirus Vaccines
- Papillomavirus Vaccines, Human
- Vaccines, Human Papillomavirus
- Human Papilloma Virus Vaccines
- HPV Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Papillomavirus Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Papillomavirus Vaccines".
This graph shows the total number of publications written about "Papillomavirus Vaccines" by people in this website by year, and whether "Papillomavirus Vaccines" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2003 | 4 | 0 | 4 |
| 2004 | 1 | 0 | 1 |
| 2006 | 6 | 0 | 6 |
| 2007 | 7 | 1 | 8 |
| 2008 | 4 | 3 | 7 |
| 2009 | 9 | 2 | 11 |
| 2010 | 8 | 3 | 11 |
| 2011 | 11 | 2 | 13 |
| 2012 | 14 | 4 | 18 |
| 2013 | 13 | 3 | 16 |
| 2014 | 12 | 2 | 14 |
| 2015 | 20 | 5 | 25 |
| 2016 | 12 | 3 | 15 |
| 2017 | 11 | 8 | 19 |
| 2018 | 14 | 5 | 19 |
| 2019 | 15 | 6 | 21 |
| 2020 | 24 | 4 | 28 |
| 2021 | 18 | 4 | 22 |
| 2022 | 27 | 0 | 27 |
| 2023 | 14 | 0 | 14 |
| 2024 | 14 | 1 | 15 |
| 2025 | 1 | 1 | 2 |
Below are the most recent publications written about "Papillomavirus Vaccines" by people in Profiles.
-
Addressing Global Disparities in Cervical Cancer Burden: A Narrative Review of Emerging Strategies. Curr HIV/AIDS Rep. 2025 Feb 21; 22(1):18.
-
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies. Hum Vaccin Immunother. 2025 Dec; 21(1):2425146.
-
Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019. J Infect Dis. 2024 Nov 15; 230(5):e1039-e1048.
-
A Self-Amplifying Human Papillomavirus 16 Vaccine Candidate Delivered by Tobacco Mosaic Virus-Like Particles. ACS Appl Bio Mater. 2024 Nov 18; 7(11):7675-7683.
-
Intervention-amenable factors associated with lack of HPV vaccination in Kenya: Results from a large national phone survey. Vaccine. 2024 Dec 02; 42(26):126410.
-
HPV Vaccination Decision Among Catch-up Population Through a Digital Intervention: Empowering Young Adults to Their Own Health Decision-Making. Cyberpsychol Behav Soc Netw. 2024 Dec; 27(12):929-938.
-
Factors Associated with HPV Vaccination Among Middle-Aged Adults in the United States. Otolaryngol Head Neck Surg. 2024 Dec; 171(6):1780-1791.
-
Acceptability of HPV vaccination for cervical cancer prevention amongst emerging adult women in rural Mysore, India: a mixed-methods study. BMC Public Health. 2024 Aug 07; 24(1):2139.
-
Knowledge of HPV vaccination and associated HNC and treatment decision-making among minority populations. Am J Otolaryngol. 2024 Nov-Dec; 45(6):104458.
-
Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings. Vaccine. 2024 Nov 14; 42(25):126129.